Information Provided By: 
Fly News Breaks for September 9, 2019
ACAD
Sep 9, 2019 | 11:41 EDT
Cowen analyst Ritu Baral raised her price for Acadia to $66 from $42 after the company's Phase 3 HARMONY study of pima in DRP hit statistical significance in an interim analysis despite a very high statistical hurdle. The analyst thinks this trial likely generated data supportive of clinically compelling benefit and excellent safety, and believes HARMONY and other supportive Phase 2/post-hoc analysis is enough to drive FDA approval. Overall, Baral sees DRP as a "blockbuster opportunity."
News For ACAD From the Last 2 Days
There are no results for your query ACAD
